BEF, Author at The Boomer Esiason Foundation

March 19, 2019

The Boomer Esiason Foundation has joined with Samsung Hope for Children, the national philanthropic initiative of the world's technology leader, and Sears to launch a new social action campaign, "Tackle CF with Boomer Esiason." The new initiative will benefit the former NFL quarterback's foundation, which...

iTunes Offers New App for Jerry Cahill’s CF Podcasts

by BEF

Boomer Esiason Foundation, CF News

March 19, 2019

The Boomer Esiason Foundation is pleased to announce that the cystic fibrosis podcast series produced by BEF Volunteer Jerry Cahill now is available on your iPhone, iPad or iPod Touch. A new iTunes app made specifically for Jerry’s podcasts offers these features: streaming access to play...

BEF Awards $10,000 Scholarships to Two Student-Athletes

by BEF

Boomer Esiason Foundation, CF News

March 19, 2019

The Boomer Esiason Foundation has awarded $10,000 scholarships to two college freshmen with cystic fibrosis. In addition to demonstrating academic success, community involvement, financial need and compliance with CF therapies, applicants for the Exercise for Life scholarship are required to keep a running log for 12...

AbbVie and Galapagos to Co-Develop CF Therapies

by BEF

CF News, Therapies

March 19, 2019

Sep 24, 2013 SOURCE: ABBVIE NORTH CHICAGO, Ill. and MECHELEN, Belgium, Sept. 24, 2013 /PRNewswire/ -- Galapagos NV (Euronext: GLPG) and AbbVie (NYSE: ABBV) announced today that they have entered into a global alliance to discover, develop and commercialize novel potentiator and combination therapies in cystic fibrosis...

Cornerstone Therapeutics Inc. announced it is now actively marketing PERTZYE® in the US

by BEF

CF News, Therapies

March 19, 2019

SOURCE Cornerstone Therapeutics Initiates PERTZYE(R) (pancrelipase) Sales and Marketing Efforts for the Treatment of Exocrine Pancreatic Insufficiency in Patients With Cystic Fibrosis CARY, NC--(Marketwired - Jul 29, 2013) - Cornerstone Therapeutics Inc. (NASDAQ: CRTX) announced today it is now actively marketing PERTZYE® (pancrelipase) in the U.S. for...

FDA Approves New Powder form of Novartis TOBI

by BEF

CF Community, CF News, Therapies

March 19, 2019

A dry powder form of the antibiotic TOBI - TOBI Podhaler (tobramycin inhalation powder) - used to treat lung infections caused by the bacteria Pseudomonas aeruginosa has been approved by the US Food and Drug Administration (FDA). People with CF ages six and older who have Pseudomonas aeruginosa and...

PTC Therapeutics Announces Promising Results from Phase 3 Trial of Ataluren

by BEF

CF News, Therapies

March 19, 2019

Source: Cystic Fibrosis Foundation PTC Therapeutics Inc. recently announced results from a Phase 3 clinical trial of ataluren, a potential oral drug aimed at treating the underlying cause of cystic fibrosis. The 48-week study tested ataluren in people with CF ages six and older who have what...

Progress Made on Cayston® Supply Challenges, CFF Reports

by BEF

CF Community, CF News, Therapies

March 19, 2019

Source: Cystic Fibrosis Foundation Gilead Sciences Inc. announced this week it has made progress resolving a shortage of its inhaled antibiotic Cayston® that began earlier this year. The company said it expects it will be able to lift the restrictions on the drug’s supply in early...

FDA Approves New Drug Application for Digestive Care’s PERTZYE

by BEF

CF News, Therapies

March 19, 2019

Digestive Care, Inc. (DCI), announced it has received U.S. Food and Drug Administration (FDA) approval of its new drug application for PERTZYE™, indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions. PERTZYE is a unique pancreatic enzyme product containing bicarbonate-buffered...

Vertex Reports Promising Interim Results for Phase 2 Trial of Kalydeco and VX-809

by BEF

CF News, Therapies

March 19, 2019

Source: Cystic Fibrosis Foundation Vertex Pharmaceuticals Inc. today announced promising interim results from a Phase 2 clinical trial of its cystic fibrosis drug Kalydeco™ and VX-809, a CF drug in development. The results showed a significant improvement in lung function in people with two copies of the...

Author: BEF

Samsung, Sears and BEF Team Up to Tackle Cystic Fibrosis

iTunes Offers New App for Jerry Cahill’s CF Podcasts

BEF Awards $10,000 Scholarships to Two Student-Athletes

AbbVie and Galapagos to Co-Develop CF Therapies

Cornerstone Therapeutics Inc. announced it is now actively marketing PERTZYE® in the US

FDA Approves New Powder form of Novartis TOBI

PTC Therapeutics Announces Promising Results from Phase 3 Trial of Ataluren

Progress Made on Cayston® Supply Challenges, CFF Reports

FDA Approves New Drug Application for Digestive Care’s PERTZYE

Vertex Reports Promising Interim Results for Phase 2 Trial of Kalydeco and VX-809

Never miss an update. Subscribe to our emails!